18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.

UNLABELLED The purpose of this study was to evaluate the ability of (18)F-FDG PET to characterize adrenal lesions in patients with proven or suspected cancers. METHODS A retrospective analysis was performed on 50 adrenal lesions in 41 patients, whose PET scans were done to evaluate the primary or metastatic disease. CT had shown 50 adrenal lesions in 41 patients and MRI had revealed 13 lesions in 10 patients. There were 34 patients with proven malignancy (28 lung cancer, 3 thyroid cancer, 2 colorectal cancer, and 1 lymphoma) and 7 with lung nodules. Of the 50 lesions, 18 were eventually determined to be malignant either by histopathology (n = 7) or by follow-up (n = 11). The remaining 32 lesions were proven or assumed to be benign by histopathology (n = 4) or clinical follow-up (n = 28). Unlike previously published reports, PET was interpreted as positive if the uptake was equal to or greater than that of the liver. RESULTS No malignant lesion yielded a negative result on PET. Most lesions (13/18) showed significantly higher FDG uptake than that of the liver. In the remaining 5 lesions (2 metastases from neuroendocrine tumor, 2 early metastases, and 1 necrotic metastasis), FDG uptake was equal to or slightly higher than that of the liver. Of the 32 benign lesions, there were 2 lesions with uptake equal to or slightly higher than that of the liver, 3 with uptake less than the liver but more than the background, and 27 with uptake of the background. MRI identified 3 of the 13 lesions as false-positives but FDG PET correctly identified all 3 as benign. The other 10 adrenal lesions accurately diagnosed by MRI were also characterized by PET. FDG PET for characterization of adrenal lesions showed a sensitivity of 100%, a specificity of 94%, and an accuracy of 96%. CONCLUSION FDG PET showed excellent diagnostic performance in differentiating adrenal lesions detected on CT or MRI. Because FDG PET has the additional advantage of evaluating the primary lesions as well as metastases, it could be cost-effective and the modality of choice for the characterization of adrenal lesions, especially in patients with malignancy.

[1]  H. Hedeland,et al.  On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. , 2009, Acta medica Scandinavica.

[2]  M. Goldberg,et al.  Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[3]  G Muehllehner,et al.  Singles transmission in volume-imaging PET with a 137Cs source. , 1995, Physics in medicine and biology.

[4]  B. Alfano,et al.  Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. , 1999, AJR. American journal of roentgenology.

[5]  P R Mueller,et al.  Adrenal masses: characterization with delayed contrast-enhanced CT. , 1997, Radiology.

[6]  P. Hahn,et al.  An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. , 1995, AJR. American journal of roentgenology.

[7]  Risk factors and long-term follow-up of adrenal incidentalomas. , 1999, The Journal of clinical endocrinology and metabolism.

[8]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[9]  M. Boscaro,et al.  Diagnosis and management of adrenal incidentalomas. , 2000, The Journal of urology.

[10]  D. Szolar,et al.  Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. , 1998, Radiology.

[11]  G. Boland,et al.  The incidental nonhyperfunctioning adrenal mass: an imaging algorithm for characterization. , 1998, Clinical radiology.

[12]  D. Farley,et al.  Can Adrenal Incidentalomas Be Safely Observed? , 1998, World Journal of Surgery.

[13]  R. Reznek,et al.  Imaging of incidentally discovered adrenal masses , 1998, Clinical endocrinology.

[14]  P C Goodman,et al.  Evaluation of primary pulmonary carcinoid tumors using FDG PET. , 1998, AJR. American journal of roentgenology.

[15]  L E Quint,et al.  Delayed enhanced CT for differentiation of benign from malignant adrenal masses. , 1996, Radiology.

[16]  D. Ross,et al.  Incidentally discovered adrenal masses. , 1989, American journal of surgery.

[17]  D. Mitchell,et al.  Benign adrenocortical masses: diagnosis with chemical shift MR imaging. , 1992, Radiology.

[18]  Norman Goldstein,et al.  Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.

[19]  L. Quint,et al.  CT time-attenuation washout curves of adrenal adenomas and nonadenomas. , 1998, AJR. American journal of roentgenology.

[20]  R. Commons,et al.  Adenomas of the adrenal cortex. , 1948, Archives of internal medicine.

[21]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[22]  T. Egglin,et al.  Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. , 1991, Radiology.

[23]  J S Karp,et al.  Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. , 1998, European journal of nuclear medicine.

[24]  R. Semelka,et al.  Adrenocortical carcinoma: MR imaging appearance with current techniques , 1995, Journal of magnetic resonance imaging : JMRI.

[25]  P M Copeland,et al.  The incidentally discovered adrenal mass. , 1983, Annals of surgery.

[26]  M. Bernardino,et al.  Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. , 1984, Radiology.

[27]  N. Papanicolaou,et al.  Current concepts in imaging of adrenal masses , 1999, World Journal of Urology.